精确放疗治疗原发性肝癌后HBV再激活的影响因素研究

摘要/Abstract

摘要： 目的: 探讨精确放疗治疗原发性肝癌(PLC)后乙型肝炎病毒(HBV)再激活的影响因素。方法: 2016年5月—2019年5月解放军联勤保障部队第九○四医院收治的PLC患者138例,均接受精确放疗治疗。统计患者肿瘤直径、肝功能Child-Pugh分级、HBV?DNA等一般资料,分析精确放疗后HBV再激活发生情况,并采用多因素logistic回归分析PLC患者精确放疗后HBV再激活的独立影响因素。结果: 138例PLC患者均行精确放疗,有34例(24.6%)发生HBV再激活,其中精确放疗后4周发生6例(4.3%),8周发生16例(11.6%),12周发生12例(8.7%),均纳入HBV再激活组;104例(75.4%)未发生HBV再激活,归入HBV未激活组。HBV再激活组肝功能Child-Pugh分级为B级所占比例为58.8%,显著高于HBV未激活组的14.4%(P<0.05);HBV再激活组血清HBV DNA ＞1.0×10⁴拷贝/mL所占比例为50.0%,显著高于HBV未激活组的6.7%(P<0.05)。多因素logistic回归分析显示,肝Child-Pugh分级(OR=1.129,95%CI=1.004～1.270)、血清HBV DNA(OR=1.146,95%CI=1.028～1.278)是PLC患者精确放疗后HBV再激活的独立影响因素(P<0.05)。结论: PLC患者精确放疗后HBV再激活与肝Child-Pugh分级、血清HBV DNA水平密切相关,临床应引起足够重视。

关键词: 精确放疗, 原发性肝癌, 乙型肝炎病毒再激活, HBV DNA

Abstract: Objective Objective To explore the influencing factors of reactivation of hepatitis B virus (HBV) after precise radiotherapy for primary liver cancer (PLC). Methods From May 2016 to may 2019, 138 PLC patients in our hospital received precise radiotherapy.The tumor diameter, child-pugh grade of liver function, HBV DNA and other general data of patients were counted to analyze the occurrence of HBV reactivation after precise radiotherapy, and multivariate Logistic regression was used to analyze the independent influencing factors of HBV reactivation after precise radiotherapy in patients with PLC. Results All 138 PLC patients received precise radiotherapy, and 34 (24.6%) had HBV reactivation, including 6 (4.3%) at 4 weeks after precise radiotherapy, 16 (11.6%) at 8 weeks, and 12 (8.7%) at 12 weeks, all of which were included in the HBV reactivation group;104 patients (75.4%) did not experience HBV reactivation and were included in the HBV inactive group.The proportion of child-pugh grade B in the HBV reactivation group was 58.8%, significantly higher than 14.4% in the non-activated group (P<0.05);The proportion of serum HBV DNA > 1.0×10⁴ copies /ml in the HBV reactivation group was 50.0%, significantly higher than 6.7% in the non-activated group (P<0.05).Multivariate Logistic regression analysis showed that child-pugh grade (OR=1.129, 95%CI=1.004~1.270) and serum HBV DNA (OR=1.146, 95%CI=1.028~1.278) were independent influencing factors for HBV reactivation in PLC patients after accurate radiotherapy (P<0.05). Conclusion The reactivation of HBV in PLC patients after precise radiotherapy is closely related to the child Pugh grade of liver and the level of HBV DNA in serum, which should be paid more attention in clinical practice.

Key words: Precise radiotherapy, Primary liver cancer, Reactivation of hepatitis B virus, HBV DNA

王骁, 周锡建, 顾培. 精确放疗治疗原发性肝癌后HBV再激活的影响因素研究[J]. 肝脏, 2020, 25(7): 702-704.

WANG Xiao, ZHOU Xi-jian, GU Pei. Study on the influencing factors of HBV reactivation after precise radiotherapy for primary liver cancer[J]. Chinese Hepatolgy, 2020, 25(7): 702-704.

参考文献

[1] 黄培新, 王娜, 钱俊华,等. 江苏省海门市原发性肝癌队列随访结果分析. 中华流行病学杂志, 2017, 38(10):1376-1379.
[2] 翟志超, 任为正, 刘志伟, 等. 解剖性与非解剖性肝切除治疗原发性肝癌远期疗效的比较. 中华肝胆外科杂志, 2017, 23(11):771-775.
[3] 徐勇, 冯继红. TACE联合核苷(酸)类似物抗病毒治疗乙肝相关性肝癌的疗效观察. 大连医科大学学报, 2016, 38(3):264-268.
[4] 赵建国. 介入栓塞联合精确放疗治疗原发性肝癌的临床效果及生活质量评价. 肝脏, 2015, 20(12):991-993.
[5] 张秋明, 钟鉴宏, 游雪梅, 等. 核苷类似物联合TACE治疗HBV相关性肝细胞癌的预后分析. 肿瘤防治研究, 2016, 43(9):792-795.
[6] 芦东徽, 唐隽, 周俊平,等. 三维适形放射治疗联合经皮肝动脉化疗栓塞不同序贯顺序治疗原发性肝癌伴门静脉癌栓的临床对照. 中华肝脏病杂志, 2015, 23(3):184-188.
[7] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015, 21(3):145-151.
[8] 徐晨阳. 螺旋断层放射治疗技术在恶性肿瘤中的治疗进展. 肿瘤学杂志, 2018, 24(10):1002-1007.
[9] Lee MW, Park SG, Woo HY , et al. Three-dimensional conformal radiotherapy for portal vein tumor thrombosis in advanced hepatocellular carcinoma. Gastroenterology, 2017, 152(5):S1175-S1176.
[10] Paul S , Saxena A , Terrin N , et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med, 2016, 164(1):30-40.
[11] 王凯, 倪才方, 蒋国民,等. HBV-DNA阴性肝癌肝动脉化疗栓塞后HBV再激活的临床研究. 中华肝胆外科杂志, 2017, 23(3):166-168.
[12] 王会娜, 黄伟, 刘毅慧. 原发性肝癌放疗后乙肝病毒再激活预测模型的特征降维分析. 中国生物医学工程学报, 2017, 36(6):697-701.
[13] Gong WF , Zhong JH , Lu SD , et al. Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Oncotarget, 2017, 8(9):15047-15056.
[14] 张晶晶, 曲颂, 余建荣, 等. 原发性肝癌三维适形放疗致乙型肝炎病毒再激活相关研究. 癌症进展, 2015, 13(2):183-187.
[15] Huang R , Wang J , Hao Y , et al. Letter: the potential risk of HBV reactivation in patients with resolved HBV infection during direct-acting antiviral therapy. Aliment Pharmacol Ther, 2017, 46(7):702-703.
[16] 邱菡, 王茹稼, 林玉仙. 1例原发性肝癌伴HBV再激活患者的病例分析. 北方药学, 2015, 12(10):159-160.